目的探讨熊去氧胆酸(UDCA)治疗婴儿肝炎综合征(IHS)的疗效。方法85例IHS患儿随机分为治疗组45例(男23例,女22例;平均年龄2.35个月)与对照组40例(男21例,女19例;平均年龄2.05个月)。二组病例均予保肝及基础治疗。治疗组在此基础上,加用UDCA15～25mg/(kg.d),分2、3次服用,连续应用10～15d为1个疗程,部分用2、3疗程。监测二组患儿治疗前后血清与十二指肠引流液(胆汁)中总胆红素(TB)、结合胆红素(DB)、ALT、γ-谷氨酰转肽酶(γ-GT)、总胆汁酸(TBA)水平以及肝脏大小。采用SPSS11.0软件进行统计学分析。结果采用UDCA治疗2周后,治疗组患儿血清及胆汁中TB、DB、ALT、γ-GT、TBA与对照组比较均显著降低(Pa<0.01),肝脏明显缩小(P<0.01);十二指肠引流液中TB、DB、TBA均较对照组显著升高(Pa<0.01),二组治疗后十二指肠引流液中ALT无显著性差异。二组均未见明显药物不良反应。结论UDCA能降低血清胆红素及内源性胆汁酸水平,可促进胆红素、TBA排泄,具有明显的利胆、退黄的疗效。 Objective To investigate the efficacy of ursodeoxycholic acid (UDCA) in the treatment of infant hepatitis syndrome (IHS). Methods A total of 85 IHS children were randomly divided into treatment group (23 males and 22 females; mean age 2.35 months) and control group (21 males and 19 females; mean age 2.05 months). Two groups of patients were given liver protection and basic treatment. On the basis of this, the treatment group was treated with UDCA15 ~ 25mg / (kg · d) for 2 and 3 times, and the continuous application of 10 ~ 15d for 1 course and some for 2 and 3 courses. The levels of total bilirubin (TB), bound bilirubin (DB), ALT, γ-glutamyl transpeptidase (γ-GT) in serum and duodenal drainage fluid (bile) , Total bile acid (TBA) levels, and liver size. SPSS11.0 software was used for statistical analysis. Results After treated with UDCA for 2 weeks, the levels of TB, DB, ALT, γ-GT and TBA in the serum and bile of the treatment group were significantly lower than those of the control group (P <0.01), and the liver was significantly reduced (P <0.01) The levels of TB, DB and TBA in the duodenal drainage fluid were significantly higher than those in the control group (Pa <0.01). There was no significant difference in ALT between the two groups in the drainage of the duodenum. No obvious adverse drug reaction was found in the two groups. Conclusion UDCA can reduce serum bilirubin and endogenous bile acid levels, can promote bilirubin, TBA excretion, with obvious gallbladder, jaundice curative effect.